Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer

Iguchi, Haruo; Sugano, Kentaro; Fukayama, Noriko; Ohkura, H; Sadamoto, K; Ohkoshi, Kishiko; Seo, Yousuke; Tomoda, Hirotsugu; Funakoshi, Akihiro; Wakasugi, Hideyuki

doi:10.1053/gast.1996.v110.pm8536860

Cited by 78 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we developed a one-step real-time PCR and detected K-ras mutations in approximately one-third of patients with a malignant etiology for the biliary stenosis, whereas mutations were not present in any bile from patients with benign obstructions. The mutation frequency in bile was comparable to the frequencies reported in previous studies (3,4,8,31 ). This low frequency may be explained by the scirrhous nature of cholangiocarcinoma; the extraductal growth of pancreatic cancer, which makes it difficult for the cancer cells to be exfoliated into the bile; and/or the PCR inhibitors present in bile.…”

Section: Clinical Chemistry 50 No 3 2004supporting

confidence: 83%

“…The presence of K-ras gene mutations in bile, duodenal juice, and pancreatic juice has been used to distinguish benign from malignant biliary strictures (3)(4)(5)(6)(7)(8). Although K-ras mutations have been detected in some patients with benign biliary strictures, such as chronic pancreatitis and gallstones (3,6 ), the detection of such mutations appears to be specific and is considered to be of help in differentiating benign from malignant strictures (3)(4)(5).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rapid Detection of K-ras Mutations in Bile by Peptide Nucleic Acid-mediated PCR Clamping and Melting Curve Analysis: Comparison with Restriction Fragment Length Polymorphism Analysis

Chen¹,

Shiesh

2004

Clinical Chemistry

View full text Add to dashboard Cite

Background: Current methods for detection of K-ras gene mutations are time-consuming. We aimed to develop a one-step PCR technique using fluorescent hybridization probes and competing peptide nucleic acid oligomers to detect K-ras mutations in bile and to compare the efficacy with restriction fragment length polymorphism (RFLP) analysis. Methods: Bile samples were obtained from 116 patients with biliary obstruction, including gallstones (n ‫؍‬ 64), benign biliary strictures (n ‫؍‬ 6), pancreatic cancer (n ‫؍‬ 20), and cholangiocarcinoma (n ‫؍‬ 26). The DNA was extracted and subjected to K-ras mutation analysis by real-time PCR and RFLP analysis. Mutations were confirmed by direct sequencing. The sensitivity and specificity were calculated according to the clinical results. Results: The analysis time for real-time PCR was <1 h, whereas RFLP analysis took more than 2 days. With the sensor probe designed for the GAT (G12D) mutant in codon 12 of the K-ras gene, the real-time PCR method also detected the GTT (G12V) mutant. In contrast, a specific sensor probe for the TGT (G12C) mutant detected GAT (G12D), AGT (G12S), and GTT (G12V) mutants in addition to the TGT mutant. The real-time PCR assay allowed the detection of mutation in a 3000-fold excess of wild-type bile DNA. In bile, K-ras codon 12 mutations were detected in 16 of 46 malignant

show abstract

Section: Clinical Chemistry 50 No 3 2004supporting

confidence: 83%

mentioning

confidence: 99%

Rapid Detection of K-ras Mutations in Bile by Peptide Nucleic Acid-mediated PCR Clamping and Melting Curve Analysis: Comparison with Restriction Fragment Length Polymorphism Analysis

Chen¹,

Shiesh

2004

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…In the present study, only the most frequent KRAS2 gene mutation G12D (aspartic acid) observed in pancreatic cancer (Iguchi et al, 1996;Tada et al, 1998;Castells et al, 1999; was analysed in the serum of patients and controls, in…”

Section: Discussionmentioning

confidence: 99%

“…Detection of KRAS2 mutations were first reported in surgically removed pancreatic tumoural tissue or at autopsy (Almoguera et al, 1988;Tada et al, 1991). Thereafter mutations were discovered in 63 to 83% of samples of pure pancreatic juice or main pancreatic duct brushing obtained during endoscopic retrograde pancreatography (Iguchi et al, 1996;Kondo et al, 1997;Tada et al, 1998;Van Laethem et al, 1998;Okai et al, 1999;Watanabe et al, 1999;Ha et al, 2001;Pugliese et al, 2001;Seki et al, 2001) or at fine-needle tumour aspiration (Pabst et al, 1999;Puig et al, 2000), and in 20 to 54% of stools (Caldas et al, 1994;Wenger et al, 1999) from patients with pancreatic cancer. Circulating deoxyribo nucleic acid (DNA) was first detected in serum or plasma of normal subjects in 1975 (Steinman, 1975).…”

mentioning

confidence: 99%

Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA

et al. 2002

View full text Add to dashboard Cite

KRAS2 mutations in codon 12 have been detected in about 80% of pancreatic cancers. The aim of this study was to evaluate the value of KRAS2 mutations detection in circulating deoxyribo nucleic acid to differentiate pancreatic cancer from chronic pancreatitis. Circulating deoxyribo nucleic acid was isolated from serum in 47 patients with histologically proven pancreatic adenocarcinomas (26 males, median age 65 years) and 31 controls with chronic pancreatitis (26 males, median age 48 years). Mutations at codon 12 of KRAS2 gene were searched for using polymerase chain reaction and allele specific amplification. Serum carbohydrate antigen 19.9 levels were also determined. KRAS2 mutations were found in 22 patients (47%) with pancreatic cancer and in four controls with chronic pancreatitis (13%) (P50.002). None of the latter developed a pancreatic cancer within the 36 months of median follow-up. The sensitivity, specificity, positive and negative predictive values of serum serum KRAS2 mutations for the diagnosis of pancreatic cancer were 47, 87, 85 and 52%, respectively. KRAS2 mutations were not related to age, gender, smoking habit, tumour stage, or survival. Among the 26 patients with normal or non-contributive (due to cholestasis) serum carbohydrate antigen 19.9 levels, 14 (54%) had KRAS2 mutations. The combination of KRAS2 and carbohydrate antigen 19.9 gave a sensitivity, specificity, positive and negative predictive values for the diagnosis of pancreatic cancer of 98, 77, 87 and 96%, respectively. Detection of KRAS2 mutations in circulating deoxyribo nucleic acid has a low sensitivity but a specificity about 90% for the diagnosis of pancreatic cancer. It seems particularly useful when serum carbohydrate antigen 19.9 levels are normal or inconclusive. A combined normal serum carbohydrate antigen 19.9 and absence of circulating KRAS2 mutations makes the diagnosis of pancreatic cancer extremely unlikely.

show abstract

“…This may make it a good tool for detecting pancreatic carcinomas at an early stage. 7,8 However, Yanagisawa et al 9 showed that K-ras mutations also occur in hyperplastic ductal lesions in pancreases that do not harbor any malignancy. Therefore the K-ras mutation cannot be used as a marker of pancreatic ductal adenocarcinoma.…”

mentioning

confidence: 99%

The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium

Lüttges¹,

Schlehe²,

Menke³

et al. 1999

Cancer

130

View full text Add to dashboard Cite

Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer

Cited by 78 publications

References 0 publications

Rapid Detection of K-ras Mutations in Bile by Peptide Nucleic Acid-mediated PCR Clamping and Melting Curve Analysis: Comparison with Restriction Fragment Length Polymorphism Analysis

Rapid Detection of K-ras Mutations in Bile by Peptide Nucleic Acid-mediated PCR Clamping and Melting Curve Analysis: Comparison with Restriction Fragment Length Polymorphism Analysis

Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA

The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium

Contact Info

Product

Resources

About